Bradykinin Receptor Modulators: A Powerful Tool for Preclinical Research
MediLumine has licensed a set of bradykinin receptor modulators developed by scientists at University of Sherbrooke for in vivo and in vitro research. These modulators are based in a proprietary sequence of natural and unnatural amino acids which resist enzymatic degradation, have a superior pharmacokinetic profile and are available for preclinical research exclusively through MediLumine. They have extensive related literature and are a powerful research tool for drug delivery, pharmacological research, and research into novel therapies.
Here is a list (with clickable web links) of our Bradykinin receptor modulators for in vivo and in vivo research use:
- Bradykinin B1 Receptor Antagonist (R-954)
- Bradykinin B1 Receptor Agonist (NG29)
- Bradykinin B2 Receptor Agonist (NG291)
- Bradykinin B1/B2 Receptor Agonist (B1/B2 Dimer)
Expression of Bradykinin B1 receptor is induced in various disease states like pain and cancer. Antagonism of this receptor is well known to have therapeutic indications in various disease states like cancer and pain. Inducible B1R are involved in various models of inflammation, diabetes mellitus and other types of vasculopathies, pain syndromes, cancer, angiogenesis, multiple sclerosis, epilepsy, and Alzheimer disease.
As a tool for research, bradykinin receptor agonism is used in various in-vivo animal models of disease. The blood-brain barrier (BBB), a powerful physiological barrier that seriously impairs the delivery of various therapeutic compounds to the brain (only very small percentage of agents are able to cross the barrier) can be transiently opened with agonism of the Bradykinin B2 Receptor, a receptor which is constitutively expressed. For small animal models of Glioma, the blood brain tumor barrier can be selectively opened with bradykinin B1R receptor agonism thus increasing delivery of imaging agents and anticancer drugs to the brain tumor.
- Fernandes PD, Gomes N de M, Sirois P. The bradykinin B1 receptor antagonist R-954 inhibits Ehrlich tumor growth in rodents. Peptides. 2011 32: 1849–1854
- Kaufman GN, Zaouter C, Valteau B, Sirois P, Moldovan F. Nociceptive tolerance is improved by bradykinin receptor B1 antagonism and joint morphology is protected by both endothelin type A and bradykinin receptor B1 antagonism in a surgical model of osteoarthritis. Arthritis Research & Therapy. 2011;13(3):R76. doi:10.1186/ar3338.
- Catanzaro O., Capponi J. A., Michieli J., Labal E., Di Martino I., Sirois P. (2013). Bradykinin B(1) antagonism inhibits oxidative stress and restores Na+K+ ATPase activity in diabetic rat peripheral nervous system. Peptides 44, 100–104. 10.1016/j.peptides.2013.01.019
- Catanzaro O, Labal E, Andornino A, Capponi JA, Di Martino I, Sirois P. Blockade of early and late retinal biochemical alterations associated with diabetes development by the selective bradykinin B1 receptor antagonist R-954. Peptides. 2012;34:349–352.
- Catanzaro OL, Dziubecki D, Obregon P, et al. Antidiabetic efficacy of bradykinin antagonist R-954 on glucose tolerance test in diabetic type 1 mice. Neuropeptides. 2010;44:187–189.
- Vasquez-Pinto L. M., Nantel F., Sirois P., Jancar S. (2010). Bradykinin B(1) receptor antagonist R954 inhibits eosinophil activation/proliferation/migration and increases TGF-beta and VEGF in a murine model of asthma. Neuropeptides 44 107–113
Selective Opening of Blood Brain Tumor Barrier for Drug Delivery and Brain Tumor Imaging
- Côté J, Savard M, Neugebauer W, Fortin D, Lepage M, Gobeil F. Dual kinin B1 and B2 receptor activation provides enhanced blood–brain barrier permeability and anticancer drug delivery into brain tumors. Cancer Biology & Therapy. 2013;14(9):806-811.
- Côté J, Bovenzi V, Savard M, Dubuc C, Fortier A, et al. (2012) Induction of Selective Blood-Tumor Barrier Permeability and Macromolecular Transport by a Biostable Kinin B1 Receptor Agonist in a Glioma Rat Model. PLoS ONE 7(5): e37485. doi:10.1371/journal.pone.0037485
Safety and Pharmacokinetics
- Savard M, Côté J, Tremblay L, Neugebauer W, Regoli D, Gariépy S, Hébert N, Gobeil F. Safety and pharmacokinetics of a kinin B1 receptor peptide agonist produced with different counter-ions. Biol Chem 397(4): 365-372
- Savard M, Côté J, Tremblay L, Neugebauer W, Regoli D, Gariépy S, Hébert N, Gobeil F. Preclinical pharmacology, metabolic stability, pharmacokinetics and toxicology of the peptidic kinin B1 receptor antagonist R-954. Peptides. 2014 Feb;52:82-9. doi: 10.1016/j.peptides.2013.12.009. Epub 2013 Dec 18.